Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.

Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ.

Endocrinology. 2007 Feb;148(2):903-11. Epub 2006 Nov 22.

2.

PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells.

Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B.

J Cell Biochem. 2009 Feb 1;106(2):232-46. doi: 10.1002/jcb.21994.

3.
4.

Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.

Higashi Y, Holder K, Delafontaine P.

J Biol Chem. 2010 Nov 19;285(47):36361-8. doi: 10.1074/jbc.M110.137661. Epub 2010 Sep 15.

5.

Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program.

Rosen CJ, Ackert-Bicknell CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, Horton LG, Delahunty KM, Beamer WG, Sipos J, Clemmons D, Nelson T, Bouxsein ML, Horowitz M.

Bone. 2004 Nov;35(5):1046-58.

PMID:
15542029
6.

The IGF system in the neonatal ovine uterus.

Hayashi K, Carpenter KD, Welsh TH Jr, Burghardt RC, Spicer LJ, Spencer TE.

Reproduction. 2005 Mar;129(3):337-47.

7.

Exercise Regulation of Marrow Fat in the Setting of PPARĪ³ Agonist Treatment in Female C57BL/6 Mice.

Styner M, Pagnotti GM, Galior K, Wu X, Thompson WR, Uzer G, Sen B, Xie Z, Horowitz MC, Styner MA, Rubin C, Rubin J.

Endocrinology. 2015 Aug;156(8):2753-61. doi: 10.1210/en.2015-1213. Epub 2015 Jun 8.

8.

Changes in the insulin-like growth factor-system may contribute to in vitro age-related impaired osteoblast functions.

Kveiborg M, Flyvbjerg A, Rattan SI, Kassem M.

Exp Gerontol. 2000 Oct;35(8):1061-74.

PMID:
11121690
9.

Mutations in the NSD1 gene in patients with Sotos syndrome associate with endocrine and paracrine alterations in the IGF system.

De Boer L, Van Duyvenvoorde HA, Willemstein-Van Hove EC, Hoogerbrugge CM, Van Doorn J, Maassen JA, Karperien M, Wit JM.

Eur J Endocrinol. 2004 Sep;151(3):333-41.

10.

The mRNA expression of the members of the IGF-system in bovine corpus luteum during induced luteolysis.

Neuvians TP, Pfaffl MW, Berisha B, Schams D.

Domest Anim Endocrinol. 2003 Nov;25(4):359-72.

PMID:
14652136
11.
12.

DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.

Le H, Arnold JT, McFann KK, Blackman MR.

Am J Physiol Endocrinol Metab. 2006 May;290(5):E952-60. Epub 2005 Dec 20.

13.
15.

Partial agonist, telmisartan, maintains PPARĪ³ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass.

Kolli V, Stechschulte LA, Dowling AR, Rahman S, Czernik PJ, Lecka-Czernik B.

PLoS One. 2014 May 8;9(5):e96323. doi: 10.1371/journal.pone.0096323. eCollection 2014.

18.

Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation.

Muhlhausler BS, Morrison JL, McMillen IC.

Endocrinology. 2009 Sep;150(9):4287-94. doi: 10.1210/en.2009-0462. Epub 2009 Jun 11.

PMID:
19520784
19.
20.

Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.

Kast-Woelbern HR, Dana SL, Cesario RM, Sun L, de Grandpre LY, Brooks ME, Osburn DL, Reifel-Miller A, Klausing K, Leibowitz MD.

J Biol Chem. 2004 Jun 4;279(23):23908-15. Epub 2004 Apr 8.

Supplemental Content

Support Center